Connect with us

Hi, what are you looking for?

DOGE0.070.84%SOL19.370.72%USDC1.000.01%BNB287.900.44%AVAX15.990.06%XLM0.080.37%
USDT1.000%XRP0.392.6%BCH121.000.75%DOT5.710.16%ADA0.320.37%LTC85.290.38%
THE BIZNOB – Global Business & Financial News – A Business Journal – Focus On Business Leaders, Technology – Enterpeneurship – Finance – Economy – Politics & LifestyleTHE BIZNOB – Global Business & Financial News – A Business Journal – Focus On Business Leaders, Technology – Enterpeneurship – Finance – Economy – Politics & Lifestyle

Business

Business

AstraZeneca withdraws Covid-19 vaccine citing low demand

AstraZeneca withdraws Covid-19
Antonio Masiello/Getty Images Antonio Masiello/Getty Images
AstraZeneca withdraws Covid-19
Antonio Masiello/Getty Images Antonio Masiello/Getty Images

Listen to the article now

As a result of falling demand and the introduction of competing vaccines, AstraZeneca has decided to discontinue production of the Vaxzevria coronavirus vaccine. With almost 3 billion doses administered worldwide since its launch in January 2021, the vaccine—developed in conjunction with the University of Oxford—has been a prominent participant in the global vaccination effort.

Having said that, the corporation has admitted that the vaccine has not brought in any money since April 2023. Reduced demand has led AstraZeneca to begin the process of withdrawing marketing authorizations for Vaxzevria in Europe.

There will be no more marketing or sale of Vaxzevria in nations of the European Union as the withdrawal has been certified by the European Medicines Agency. AstraZeneca intends to collaborate with foreign regulators to revoke marketing authorizations in areas where the company does not anticipate future commercial demand.

Regardless of the withdrawal, AstraZeneca was proud of Vaxzevria’s contribution to the worldwide response to the epidemic. On the other hand, Dr. Michael Head of the University of Southampton pointed out that alternative vaccines, especially mRNA vaccines made by companies like Pfizer and Moderna, are better since they are more effective and can adapt to new strains.

Problems have arisen along the way for AstraZeneca and Vaxzevria, including criticism for blunders made during clinical trials, delays in production, and worries about uncommon side effects including blood clotting. Regardless of these obstacles, the vaccine nonetheless managed to sell well in 2021, even though AstraZeneca is currently dealing with a class action litigation in the UK over purported vaccination injuries.


Comment Template

You May Also Like

Business

Biden Imposes Increased Tariffs: More and more Chinese-made commodities, including electric automobiles, solar panels, steel, and more, are subject to higher tariffs. These tariffs...

Business

At a turning point in the Horizon IT Inquiry, Post Office lawyer Simon Clarke revealed that a crucial expert had knowledge of system flaws....

Business

EU’s von der Leyen to urge: During her meeting with Chinese President Xi Jinping, EU leader Ursula von der Leyen stressed the need for...

Business

Disney says password crackdown: As part of its plan to turn a profit from its streaming business, Disney is concentrating on releasing a flood...

Notice: The Biznob uses cookies to provide necessary website functionality, improve your experience and analyze our traffic. By using our website, you agree to our Privacy Policy and our Cookie Policy.

Ok